NeRRe Therapeutics raises £20 million in a Series B2 financing round

7 de July de 2021

NeRRe Therapeutics raises £20 million in a Series B2 financing round

  • New funds to evaluate orvepitant as a treatment for the disabling chronic cough
    associated with idiopathic pulmonary fibrosis (IPF).
  •  New investor Columbus Venture Partners joins existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, and the UK Government’s Future Fund.

Read more

Contact us

Columbus Venture Partners
Ronda Guglielmo Marconi, 8.
46980 – Parque Tecnológico (Valencia)

    Before giving your consent, please read the information on data protection
    +

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.